EGFR expression levels have been linked to radioresistance23,24, and a phase III trial showed improved overall survival in HNSCC patients treated with the EGFR-inhibitor cetuximab plus radiotherapy25. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.